204 related articles for article (PubMed ID: 9846166)
21. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation.
DeBell WK; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1991 Jun; 72(6):1312-6. PubMed ID: 2026752
[TBL] [Abstract][Full Text] [Related]
22. Ipamorelin, the first selective growth hormone secretagogue.
Raun K; Hansen BS; Johansen NL; Thøgersen H; Madsen K; Ankersen M; Andersen PH
Eur J Endocrinol; 1998 Nov; 139(5):552-61. PubMed ID: 9849822
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
[TBL] [Abstract][Full Text] [Related]
24. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats.
Thomas GB; Fairhall KM; Robinson IC
Endocrinology; 1997 Apr; 138(4):1585-91. PubMed ID: 9075719
[TBL] [Abstract][Full Text] [Related]
25. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.
Rigamonti AE; Cella SG; Marazzi N; Müller EE
Eur J Endocrinol; 1999 Sep; 141(3):313-20. PubMed ID: 10474131
[TBL] [Abstract][Full Text] [Related]
26. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
[TBL] [Abstract][Full Text] [Related]
27. Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585.
Fairhall KM; Mynett A; Smith RG; Robinson IC
J Endocrinol; 1995 Jun; 145(3):417-26. PubMed ID: 7636426
[TBL] [Abstract][Full Text] [Related]
28. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
Veldhuis JD; Evans WS; Bowers CY
J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
[TBL] [Abstract][Full Text] [Related]
29. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
[TBL] [Abstract][Full Text] [Related]
30. Modulation of growth hormone-releasing activity of hexarelin in man.
Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
[TBL] [Abstract][Full Text] [Related]
31. No desensitization of the growth hormone (GH) response between GH-releasing peptide-2 and GH-releasing factor in calves.
Roh SG; He ML; Matsunaga N; Hidaka S; Hidari H
J Anim Sci; 1997 Oct; 75(10):2749-53. PubMed ID: 9331880
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves.
Roh SG; Matsunaga N; Hidaka S; Hidari H
Endocr J; 1996 Jun; 43(3):291-8. PubMed ID: 8886623
[TBL] [Abstract][Full Text] [Related]
33. Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine.
Phung LT; Sasaki A; Lee HG; Vega RA; Matsunaga N; Hidaka S; Kuwayama H; Hidari H
Domest Anim Endocrinol; 2001 Jan; 20(1):9-19. PubMed ID: 11164330
[TBL] [Abstract][Full Text] [Related]
34. The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects.
Rahim A; O'Neill P; Shalet SM
Clin Endocrinol (Oxf); 1998 Nov; 49(5):659-64. PubMed ID: 10197083
[TBL] [Abstract][Full Text] [Related]
35. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
36. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action.
Fairhall KM; Mynett A; Robinson IC
J Endocrinol; 1995 Mar; 144(3):555-60. PubMed ID: 7738479
[TBL] [Abstract][Full Text] [Related]
37. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats.
Deghenghi R; Cananzi MM; Torsello A; Battisti C; Muller EE; Locatelli V
Life Sci; 1994; 54(18):1321-8. PubMed ID: 7910650
[TBL] [Abstract][Full Text] [Related]
38. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.
Tiulpakov AN; Brook CG; Pringle PJ; Peterkova VA; Volevodz NN; Bowers CY
Clin Endocrinol (Oxf); 1995 Sep; 43(3):347-50. PubMed ID: 7586605
[TBL] [Abstract][Full Text] [Related]
39. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly.
Giustina A; Bresciani E; Bugari G; Bussi AR; Deghenghi R; Imbimbo B; Giustina G
Endocr Res; 1995 Aug; 21(3):569-82. PubMed ID: 7588427
[TBL] [Abstract][Full Text] [Related]
40. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
Kelijman M; Frohman LA
J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
